AF-710B
- Generic Name
- AF-710B
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N3OS
- CAS Number
- 1235733-73-9
- Unique Ingredient Identifier
- AAE07Z061B
Anavex's Blarcamesine Shows Promise in Long-Term Alzheimer's Treatment, EMA Filing Accepted
• Anavex Life Sciences' blarcamesine demonstrates sustained cognitive and functional benefits in early Alzheimer's patients over three years of continuous oral treatment.
• The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for blarcamesine, a potential novel oral treatment for Alzheimer's disease.
• Blarcamesine targets upstream Alzheimer's pathology through autophagy enhancement and has shown a favorable safety profile in clinical trials.
• Anavex is also evaluating blarcamesine for other CNS indications, including Parkinson’s disease and Rett syndrome.
Anavex Life Sciences Announces EMA Acceptance of Blarcamesine MAA for Alzheimer's Treatment
• The European Medicines Agency (EMA) has accepted Anavex's Marketing Authorization Application (MAA) for blarcamesine to treat Alzheimer's disease.
• Anavex presented Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial data at the J.P. Morgan 2025 Healthcare Conference.
• Preliminary Phase 2 clinical study results of ANAVEX3-71 for schizophrenia showed a dose-dependent effect on key EEG biomarkers.
• Anavex reported a strong cash position of $132.2 million, anticipating a cash runway of approximately four years.
Anavex Life Sciences Awaits Topline Results from Rett Syndrome Trial
• Anavex Life Sciences is developing Anavex 2-73, a small molecule targeting the sigma-1 receptor, for neurodegenerative and neurodevelopmental disorders.
• The EXCELLENCE trial, a phase II/III study of Anavex 2-73 in pediatric Rett syndrome patients, is expected to release topline data in the coming months.
• Anavex 2-73 has demonstrated statistically significant cognitive improvement in a phase 2b/3 study for early Alzheimer's disease.
• The company's pipeline also includes ANAVEX 3-71, targeting SIGMAR1 and muscarinic receptors, currently in phase I trials for Frontotemporal Dementia, Schizophrenia, and Alzheimer's.
Anavex's ANAVEX3-71 Shows Promise in Schizophrenia Phase 2 Trial with EEG Biomarker Improvements
• Anavex Life Sciences reports positive preliminary results from its Phase 2 trial of ANAVEX3-71 in schizophrenia, showing dose-dependent effects on EEG biomarkers.
• The trial demonstrated that ANAVEX3-71 improved 40 Hz Auditory Steady-State Response (ASSR) Inter Trial Coherence (ITC) and Resting State Alpha Power compared to placebo.
• ANAVEX3-71 was well-tolerated, with no serious adverse events reported, suggesting potential for a novel treatment approach for schizophrenia.
• Part B of the Phase 2 study is ongoing with more participants and longer treatment duration, with data expected in the first half of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath